腫瘤細胞減滅術治療復發上皮性卵巢癌的系統分析_《華西醫學》

作者：

黨彩玲 ^1,2 , 趙丹 ³ , 陽志軍 ¹ ,  李力 ¹

1 廣西醫科大學附屬腫瘤醫院婦瘤科（南寧，530021）;2 宜賓市第二人民醫院婦科;3 宜賓市第一人民醫院血液腫瘤科;

關鍵詞：

復發上皮性卵巢癌腫瘤細胞減滅術系統評價

DOI：

10.7507/1002-0179.20130531

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　評價腫瘤細胞減滅術治療復發上皮性卵巢癌（EOC）的作用，分析影響生存時間的因素。方法　按Cochrane系統評價方法，計算機檢索PubMed、EMbase、Medline、Cochrane Library、循證醫學數據庫（EBMR）、中國生物醫學文獻數據庫（CBM）、中國期刊全文數據庫（CJFD）、清華同方等數據庫，并手工檢索相關領域雜志。檢索時間從1985年1月1日－2011年11月30日，查找手術治療復發EOC患者的回顧性、非隨機前瞻性、病例對照研究，由兩位研究者按照納入排除標準篩選文獻、評價質量并提取資料后，采用SPSS軟件進行線性回歸分析。結果　共納入48篇文獻（回顧性文獻40篇，非隨機前瞻性文獻7篇，病例對照研究1篇）共2 605例。簡單線性回歸分析結果顯示滿意切除比例與中位生存時間回歸模型成立，有統計學意義（F=7.346，P=0.009），漿液性病理類型比例與中位生存時間回歸模型成立，有統計學意義（F=5.537，P=0.025），殘留病灶大小與中位生存時間回歸模型成立，有統計學意義（F=4.249，P=0.045），多重逐步線性回歸分析顯示僅有滿意切除比率對術后中位生存時間的影響有統計學意義（P=0.009）。結論　二次腫瘤細胞減滅術主要適用于鉑類敏感型可切除及孤立結節復發EOC患者，要獲得明確二次腫瘤細胞減滅術治療復發EOC對中位生存時間的影響，尚需進行大樣本隨機對照的研究。

引用本文： 黨彩玲,趙丹,陽志軍,李力. 腫瘤細胞減滅術治療復發上皮性卵巢癌的系統分析. 華西醫學, 2013, 28(11): 1678-1685. doi: 10.7507/1002-0179.20130531 復制

1.	Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
2.	Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma[J]. Natl Cancer Inst Monogr, 1975, 42: 101-104.
3.	Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stageⅢ epithelial ovarian cancer: a gynecologic oncology group study[J]. Gynecol Oncol, 1992, 47(2): 159-166.
4.	Hoskins WJ, Mcguire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma[J]. Am J Obstet Gynecol, 1994, 170(4): 974-980.
5.	Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer[J]. Obstet Gynecol, 1983, 61(2): 189-193.
6.	Morris M, Gershenson DM, Wharton JT, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer[J]. Gynecol Oncol, 1989, 34(3): 334-338.
7.	Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer[J]. Cancer, 1992, 70(8): 2129-2136.
8.	Segna RA, Dottino PR, Mandeli JP, et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy[J]. J Clin Oncol, 1993, 11(3): 434-439.
9.	Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study[J]. Cancer, 1995, 76(9): 1606-1614.
10.	Landoni F, Pellegrino A, Cormio G, et al. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy[J]. Acta Obstet Gynecol Scand, 1998, 77(2): 233-237.
11.	Cormio G, di Vagno G, Cazzolla A, et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature[J]. Eur J Obstet Gynecol Reprod Biol, 1999, 86(2): 185-188.
12.	Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer[J]. J Surg Oncol, 2000, 75(1): 24-30.
13.	Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma[J]. Cancer, 2000, 88(1): 144-153.
14.	Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer[J]. Gynecol Oncol, 2000, 79(3): 344-349.
15.	Zylberberg B, Dormont D, Janklewicz S, et al. Secondary cytoreductions in the treatment of ovarian cancers[J]. Gynecol Obstet Fertil, 2000, 28(2): 127-136.
16.	Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer[J]. Obstet Gynecol, 2002, 99(6): 1008-1013.
17.	Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma[J]. Cancer, 2002, 95(4): 791-800.
18.	Merideth MA, Cliby WA, Keeney GL, et al. Hepatic resection for metachronous metastases from ovarian carcinoma[J]. Gynecol Oncol, 2003, 89(1): 16-21.
19.	Yoon SS, Jarnagin WR, Fong Y, et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver[J]. Gynecol Oncol, 2003, 91(2): 383-388.
20.	Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum[J]. Int J Gynecol Cancer, 2003, 13(6): 764-770.
21.	Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer[J]. World J Surg, 2004, 28(10): 1040-1045.
22.	Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes[J]. Ann Surg Oncol, 2004, 11(7): 658-664.
23.	Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?[J]. Cancer, 2004, 100(6): 1152-1161.
24.	Leitao MJ, Kardos S, Barakat RR, et al. Tertiary cytoreduction in patients with recurrent ovarian carcinoma[J]. Gynecol Oncol, 2004, 95(1): 181-188.
25.	Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection[J]. Br J Cancer, 2005, 92(6): 1026-1032.
26.	Gungor M, Ortac F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer[J]. Gynecol Oncol, 2005, 97(1): 74-79.
27.	Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum[J]. Eur J Surg Oncol, 2005, 31(1): 67-73.
28.	Ayhan A, Gultekin M, Taskiran C, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience[J]. Am J Obstet Gynecol, 2006, 194(1): 49-56.
29.	Chi DS, Mccaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma[J]. Cancer, 2006, 106(9): 1933-1939.
30.	Manci N, Bellati F, Muzii L, et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data[J]. Ann Surg Oncol, 2006, 13(12): 1717-1723.
31.	Matsumoto A, Higuchi T, Yura S, et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy[J]. J Obstet Gynaecol Res, 2006, 32(6): 580-587.
32.	Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial[J]. Ann Surg Oncol, 2006, 13(12): 1702-1710.
33.	Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns[J]. Gynecol Oncol, 2006, 103(3): 977-984.
34.	Bosquet JG, Merideth MA, Podratz KC, et al. Hepatic resection for metachronous metastases from ovarian carcinoma[J]. HPB (Oxford), 2006, 8(2): 93-96.
35.	Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients[J]. World J Surg, 2007, 31(9): 1813-1820.
36.	Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2007, 104(3): 686-690.
37.	Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome[J]. Cancer, 2007, 109(4): 685-691.
38.	Benedetti PP, Perniola G, Angioli R, et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery[J]. Int J Gynecol Cancer, 2007, 17(6): 1245-1251.
39.	Benedetti PP, de Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer[J]. Ann Surg Oncol, 2007, 14(3): 1136-1142.
40.	Helm CW, Randall-Whitis L, Martin RR, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma[J]. Gynecol Oncol, 2007, 105(1): 90-96.
41.	Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J]. Gynecol Oncol, 2007, 106(3): 482-487.
42.	Cheng X, Jiang R, Li ZT, et al. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC)[J]. Eur J Surg Oncol, 2009, 35(10): 1105-1108.
43.	Bristow RE, Peiretti M, Gerardi M, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome[J]. Gynecol Oncol, 2009, 114(2): 173-177.
44.	Fotiou S, Aliki T, Petros Z, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer[J]. Gynecol Oncol, 2009, 114(2): 178-182.
45.	Pavlov MJ, Kovacevic PA, Ceranic MS, et al. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer: 12-year single center experience[J]. Eur J Surg Oncol, 2009, 35(11): 1186-1191.
46.	Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer[J]. Ann Oncol, 2009, 20(2): 286-293.
47.	Woelber L, Jung S, Eulenburg C, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer[J]. Eur J Surg Oncol, 2010, 36(6): 583-588.
48.	Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction[J]. J Surg Oncol, 2010, 101(3): 244-250.
49.	Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery[J]. Gynecol Oncol, 2010, 116(3): 497-501.
50.	Gadducci A, Cosio S, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study[J]. Gynecol Oncol, 2010, 116(3): 358-363.
51.	Schorge JO, Wingo SN, Bhore R, et al. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer[J]. Int J Gynaecol Obstet, 2010, 108(2): 123-127.
52.	Frenel JS, Leux C, Pouplin L, et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients[J]. J Surg Oncol, 2011, 103(1): 10-16.
53.	Fotopoulou C, Richter R, Braicu IE, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer[J]. Ann Surg Oncol, 2011, 18(1): 49-57.
54.	Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2009, 112(1): 265-274.
55.	Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort[J]. Br J Cancer, 2011, 105(7): 890-896.
56.	Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer[J]. J Surg Oncol, 2010, 101(5): 418-424.

1. 　Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
2. 　Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma[J]. Natl Cancer Inst Monogr, 1975, 42: 101-104.
3. 　Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stageⅢ epithelial ovarian cancer: a gynecologic oncology group study[J]. Gynecol Oncol, 1992, 47(2): 159-166.
4. 　Hoskins WJ, Mcguire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma[J]. Am J Obstet Gynecol, 1994, 170(4): 974-980.
5. 　Berek JS, Hacker NF, Lagasse LD, et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer[J]. Obstet Gynecol, 1983, 61(2): 189-193.
6. 　Morris M, Gershenson DM, Wharton JT, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer[J]. Gynecol Oncol, 1989, 34(3): 334-338.
7. 　Janicke F, Holscher M, Kuhn W, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer[J]. Cancer, 1992, 70(8): 2129-2136.
8. 　Segna RA, Dottino PR, Mandeli JP, et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy[J]. J Clin Oncol, 1993, 11(3): 434-439.
9. 　Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study[J]. Cancer, 1995, 76(9): 1606-1614.
10. 　Landoni F, Pellegrino A, Cormio G, et al. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy[J]. Acta Obstet Gynecol Scand, 1998, 77(2): 233-237.
11. 　Cormio G, di Vagno G, Cazzolla A, et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature[J]. Eur J Obstet Gynecol Reprod Biol, 1999, 86(2): 185-188.
12. 　Zang RY, Zhang ZY, Li ZT, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer[J]. J Surg Oncol, 2000, 75(1): 24-30.
13. 　Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma[J]. Cancer, 2000, 88(1): 144-153.
14. 　Gadducci A, Iacconi P, Cosio S, et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer[J]. Gynecol Oncol, 2000, 79(3): 344-349.
15. 　Zylberberg B, Dormont D, Janklewicz S, et al. Secondary cytoreductions in the treatment of ovarian cancers[J]. Gynecol Obstet Fertil, 2000, 28(2): 127-136.
16. 　Tay EH, Grant PT, Gebski V, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer[J]. Obstet Gynecol, 2002, 99(6): 1008-1013.
17. 　Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma[J]. Cancer, 2002, 95(4): 791-800.
18. 　Merideth MA, Cliby WA, Keeney GL, et al. Hepatic resection for metachronous metastases from ovarian carcinoma[J]. Gynecol Oncol, 2003, 89(1): 16-21.
19. 　Yoon SS, Jarnagin WR, Fong Y, et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver[J]. Gynecol Oncol, 2003, 91(2): 383-388.
20. 　Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum[J]. Int J Gynecol Cancer, 2003, 13(6): 764-770.
21. 　Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer[J]. World J Surg, 2004, 28(10): 1040-1045.
22. 　Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes[J]. Ann Surg Oncol, 2004, 11(7): 658-664.
23. 　Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?[J]. Cancer, 2004, 100(6): 1152-1161.
24. 　Leitao MJ, Kardos S, Barakat RR, et al. Tertiary cytoreduction in patients with recurrent ovarian carcinoma[J]. Gynecol Oncol, 2004, 95(1): 181-188.
25. 　Onda T, Yoshikawa H, Yasugi T, et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection[J]. Br J Cancer, 2005, 92(6): 1026-1032.
26. 　Gungor M, Ortac F, Arvas M, et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer[J]. Gynecol Oncol, 2005, 97(1): 74-79.
27. 　Gronlund B, Lundvall L, Christensen IJ, et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum[J]. Eur J Surg Oncol, 2005, 31(1): 67-73.
28. 　Ayhan A, Gultekin M, Taskiran C, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience[J]. Am J Obstet Gynecol, 2006, 194(1): 49-56.
29. 　Chi DS, Mccaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma[J]. Cancer, 2006, 106(9): 1933-1939.
30. 　Manci N, Bellati F, Muzii L, et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data[J]. Ann Surg Oncol, 2006, 13(12): 1717-1723.
31. 　Matsumoto A, Higuchi T, Yura S, et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy[J]. J Obstet Gynaecol Res, 2006, 32(6): 580-587.
32. 　Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial[J]. Ann Surg Oncol, 2006, 13(12): 1702-1710.
33. 　Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns[J]. Gynecol Oncol, 2006, 103(3): 977-984.
34. 　Bosquet JG, Merideth MA, Podratz KC, et al. Hepatic resection for metachronous metastases from ovarian carcinoma[J]. HPB (Oxford), 2006, 8(2): 93-96.
35. 　Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients[J]. World J Surg, 2007, 31(9): 1813-1820.
36. 　Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2007, 104(3): 686-690.
37. 　Salani R, Santillan A, Zahurak ML, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome[J]. Cancer, 2007, 109(4): 685-691.
38. 　Benedetti PP, Perniola G, Angioli R, et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery[J]. Int J Gynecol Cancer, 2007, 17(6): 1245-1251.
39. 　Benedetti PP, de Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer[J]. Ann Surg Oncol, 2007, 14(3): 1136-1142.
40. 　Helm CW, Randall-Whitis L, Martin RR, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma[J]. Gynecol Oncol, 2007, 105(1): 90-96.
41. 　Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma[J]. Gynecol Oncol, 2007, 106(3): 482-487.
42. 　Cheng X, Jiang R, Li ZT, et al. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC)[J]. Eur J Surg Oncol, 2009, 35(10): 1105-1108.
43. 　Bristow RE, Peiretti M, Gerardi M, et al. Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome[J]. Gynecol Oncol, 2009, 114(2): 173-177.
44. 　Fotiou S, Aliki T, Petros Z, et al. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer[J]. Gynecol Oncol, 2009, 114(2): 178-182.
45. 　Pavlov MJ, Kovacevic PA, Ceranic MS, et al. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer: 12-year single center experience[J]. Eur J Surg Oncol, 2009, 35(11): 1186-1191.
46. 　Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer[J]. Ann Oncol, 2009, 20(2): 286-293.
47. 　Woelber L, Jung S, Eulenburg C, et al. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer[J]. Eur J Surg Oncol, 2010, 36(6): 583-588.
48. 　Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction[J]. J Surg Oncol, 2010, 101(3): 244-250.
49. 　Fanfani F, Fagotti A, Gallotta V, et al. Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery[J]. Gynecol Oncol, 2010, 116(3): 497-501.
50. 　Gadducci A, Cosio S, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study[J]. Gynecol Oncol, 2010, 116(3): 358-363.
51. 　Schorge JO, Wingo SN, Bhore R, et al. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer[J]. Int J Gynaecol Obstet, 2010, 108(2): 123-127.
52. 　Frenel JS, Leux C, Pouplin L, et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients[J]. J Surg Oncol, 2011, 103(1): 10-16.
53. 　Fotopoulou C, Richter R, Braicu IE, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer[J]. Ann Surg Oncol, 2011, 18(1): 49-57.
54. 　Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis[J]. Gynecol Oncol, 2009, 112(1): 265-274.
55. 　Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort[J]. Br J Cancer, 2011, 105(7): 890-896.
56. 　Park JY, Eom JM, Kim DY, et al. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer[J]. J Surg Oncol, 2010, 101(5): 418-424.

上一篇
三陰乳腺癌中C-myc和Skp2的表達及相關性研究
下一篇
秦綿祛風膠囊對鵪鶉高尿酸血癥模型的治療作用

《華西醫學》

腫瘤細胞減滅術治療復發上皮性卵巢癌的系統分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

腫瘤細胞減滅術治療復發上皮性卵巢癌的系統分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料